243 related articles for article (PubMed ID: 18845797)
1. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?
Eckman MH; Wong LK; Soo YO; Lam W; Yang SR; Greenberg SM; Rosand J
Stroke; 2008 Dec; 39(12):3308-15. PubMed ID: 18845797
[TBL] [Abstract][Full Text] [Related]
2. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis.
Eckman MH; Rosand J; Knudsen KA; Singer DE; Greenberg SM
Stroke; 2003 Jul; 34(7):1710-6. PubMed ID: 12805495
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
Eckman MH; Rosand J; Greenberg SM; Gage BF
Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
[TBL] [Abstract][Full Text] [Related]
4. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.
Middlekauff HR; Stevenson WG; Gornbein JA
Arch Intern Med; 1995 May; 155(9):913-20. PubMed ID: 7726699
[TBL] [Abstract][Full Text] [Related]
5. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.
Vestergaard AS; Skjøth F; Lip GY; Larsen TB
Stroke; 2016 Apr; 47(4):979-85. PubMed ID: 26883499
[TBL] [Abstract][Full Text] [Related]
6. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?
Paciaroni M; Agnelli G
Thromb Haemost; 2014 Jan; 111(1):14-8. PubMed ID: 24258528
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE
JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.
Senoo K; Lip GY
Stroke; 2015 Nov; 46(11):3202-7. PubMed ID: 26463692
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
11. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis.
Gerson LB; Triadafilopoulos G; Gage BF
Am J Med; 2004 Apr; 116(7):451-9. PubMed ID: 15047034
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.
Darkow T; Vanderplas AM; Lew KH; Kim J; Hauch O
Curr Med Res Opin; 2005 Oct; 21(10):1583-94. PubMed ID: 16238898
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice.
Wipf JE
West J Med; 1995 Aug; 163(2):145-52. PubMed ID: 7571562
[TBL] [Abstract][Full Text] [Related]
15. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Ahmad Y; Lip GY
Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
[TBL] [Abstract][Full Text] [Related]
16. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation.
Wysokinski WE; McBane RD; Daniels PR; Litin SC; Hodge DO; Dowling NF; Heit JA
Mayo Clin Proc; 2008 Jun; 83(6):639-45. PubMed ID: 18533080
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery.
Schulman S; Cybulsky I; Delaney J
Thromb Res; 2015 May; 135(5):841-5. PubMed ID: 25776468
[TBL] [Abstract][Full Text] [Related]
18. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
19. Resuming anticoagulant therapy after intracerebral bleeding.
Becattini C; Sembolini A; Paciaroni M
Vascul Pharmacol; 2016 Sep; 84():15-24. PubMed ID: 27260938
[TBL] [Abstract][Full Text] [Related]
20. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study.
Friberg L; Rosenqvist M; Lip GY
Circulation; 2012 May; 125(19):2298-307. PubMed ID: 22514252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
